Journal of Antimicrobial Chemotherapy (1999) 44, 455-460
© 1999 The British Society for Antimicrobial Chemotherapy
Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo
Department of Infectious Disease, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjyuku-ku, Tokyo 162-8666, Japan
Infectious disease caused by methicillin-resistant Staphylococcus aureus (MRSA) often develops in compromised hosts in whom a single administration of vancomycin is usually not effective. We assessed the combined antimicrobial effects of vancomycin and imipenem against MRSA growth in vitro as well as in vivo using a neutropenic mouse thigh infection model. Synergic and additive effects of the two drugs were observed for 34 and two, respectively, of the 36 clinical isolates of MRSA, as determined by the chequerboard method. For MRSA strain N, postantibiotic effect (PAE) values obtained in vitro were 1.9–2.6 h for vancomycin and 2.6–3.5 h for imipenem, while higher values of 2.7–4.4 h were obtained for the combination of vancomycin and imipenem. In vivo, a single administration of vancomycin at 1 or 2 mg/kg or of imipenem/cilastatin at 5 mg/kg produced growth curves similar to those in controls, with a suppressive time of 0 h. Imipenem/cilastatin at 10 mg/kg demonstrated a suppressive time of 3.1 h. Combinations of vancomycin 1 mg/kg plus imipenem/cilastatin 5 mg/kg, vancomycin 1 mg/kg plus imipenem/cilastatin 10 mg/k and vancomycin 2 mg/kg plus imipenem/cilastatin 10 mg/kg demonstrated suppressive times of 2.9, 3.9 and 5.2 h, respectively, indicating that combined administration was effective. Simultaneous administration of the two drugs was more effective than sequential administration. Thus, combined administration of vancomycin and imipenem/cilastatin proved effective for MRSA in vivo. The combined effects seemed to be synergic, since a single administration of either drug did not show anti-MRSA effects at the doses used in the combined regimen.
* Corresponding author. Tel: +81-3-3353-8111 (38311); Fax: +81-3-5269-7003; E-mail: totuka{at}clabo.zengaku.twmc.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Yanagisawa, H. Hanaki, H. Matsui, S. Ikeda, T. Nakae, and K. Sunakawa Rapid Depletion of Free Vancomycin in Medium in the Presence of {beta}-Lactam Antibiotics and Growth Restoration in Staphylococcus aureus Strains with {beta}-Lactam-Induced Vancomycin Resistance Antimicrob. Agents Chemother., January 1, 2009; 53(1): 63 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Parsonnet, R. V. Goering, M. A. Hansmann, M. B. Jones, K. Ohtagaki, C. C. Davis, and K. Totsuka Prevalence of Toxic Shock Syndrome Toxin 1 (TSST-1)-Producing Strains of Staphylococcus aureus and Antibody to TSST-1 among Healthy Japanese Women J. Clin. Microbiol., August 1, 2008; 46(8): 2731 - 2738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Li and M. C. Tang Post-antibiotic effect induced by an antibiotic combination: influence of altered susceptibility to individual components J. Antimicrob. Chemother., April 1, 2005; 55(4): 583 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jacqueline, D. Navas, E. Batard, A.-F. Miegeville, V. Le Mabecque, M.-F. Kergueris, D. Bugnon, G. Potel, and J. Caillon In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., January 1, 2005; 49(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nakamura, M. Hosoda, T. Kato, Y. Yamada, M. Itoh, K. Kanazawa, and H. Nouda Combined effects of meropenem and aminoglycosides on Pseudomonas aeruginosa in vitro J. Antimicrob. Chemother., December 1, 2000; 46(6): 901 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rochon-Edouard, M. Pestel-Caron, J.-F. Lemeland, and F. Caron In Vitro Synergistic Effects of Double and Triple Combinations of beta -Lactams, Vancomycin, and Netilmicin against Methicillin-Resistant Staphylococcus aureus Strains Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3055 - 3060. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Erjavec, H. G. de Vries-Hospers, M. Laseur, R. M. Halie, and S. Daenen A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy J. Antimicrob. Chemother., June 1, 2000; 45(6): 843 - 849. [Abstract] [Full Text] [PDF]
|
|